Aenitis Technologies
Acoustic cell processing technology for cell and gene therapy manufacturing
Paris · Founded 2015 · $16.9M raised
- Headquarters
- Paris
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- aenitis.fr
- Total Funding
- $16.9M
- Last Round
- $16.9M Venture RoundOct 2024
- Rounds
- 1
About
Aenitis Technologies is a Paris-based deeptech biotech company founded in 2014 by pioneers of acoustic levitation and fluid mechanics alongside biotech entrepreneur Emmanuel Vincent (CEO). The company develops and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. Using controlled ultrasonic waves, Aenitis' platform enables the contact-free, continuous manipulation of cells in fully sterile closed systems — supporting key unit operations including cell sorting, isolation, concentration, and washing at millifluidic scale (tens of milliliters per minute) without altering cell viability or functionality. Its flagship product, Mitis, is used across research, clinical, and industrial applications. The Modular Type Package (MTP) approach enables flexible integration of acoustic cell processing steps into existing GMP bioprocess workflows through co-development, licensing, or custom consumable integration. Aenitis has received support from the European Commission, the French Government, the European Investment Bank, and leading investors including Seventure Partners.
Summary
Aenitis Technologies is a Biotech company based in Paris, founded in 2015. It has raised $16.9M in total across 1 round, most recently a $16.9M Venture Round round in Oct 2024. Investors include European Innovation Council Fund and Seventure Partners.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2024
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...